Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in two prominent investor conferences in March 2026, underscoring the company's advancing pipeline and commercial expansion. Seth Lederman, M.D., president and chief executive officer, will present at the TD Cowen 46th Annual Healthcare Conference on March 4, 2026, at the Boston Marriott Copley Place. The presentation is scheduled from 11:10 a.m. to 11:40 a.m. ET. Additionally, Tonix management will hold one-on-one meetings at the Barclays 28th Annual Healthcare Conference from March 10 to 12 at the Loews Miami South Beach Hotel in Miami Beach.
These conferences provide a platform for Tonix to discuss its recent achievements, particularly the FDA approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg) as the first new treatment for fibromyalgia in over 15 years. TONMYA represents a significant milestone for patients suffering from this chronic pain condition, for which treatment options have been limited. Tonix is also leveraging its CNS commercial infrastructure to support its marketed acute migraine products, Zembrace SymTouch and Tosymra.
Beyond its approved products, Tonix is advancing TONMYA's potential into new indications. Phase 2 clinical trials are evaluating TONMYA for major depressive disorder and acute stress disorder, conditions with high unmet medical need. The company's CNS pipeline also includes TNX-2900, a Phase 2-ready therapy for Prader-Willi syndrome, a rare genetic disorder. Immunologically, Tonix is developing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor to prevent kidney transplant rejection.
Investors and industry analysts will have the opportunity to engage with Tonix's leadership during these conferences. The presentations will likely emphasize the company's integrated business model, spanning from research and development to commercialization. Tonix's participation in these events signals its commitment to communicating its progress and strategic vision to the investment community.
For more details on the conferences and Tonix's pipeline, refer to the full press release at https://ibn.fm/TToz2. Updates on Tonix Pharmaceuticals are available in the company's newsroom at https://ibn.fm/TNXP.
